Abstract: Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

Abstract: Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

Abstract: A contact lens having more than one configuration is disclosed herein. The optical power of the contact lens may be dynamically changed through the different configurations of the contact lens. The different configurations may be actuated using a valve. Also disclosed herein is a contact lens comprising a dimension, which contact lens is configured to have the dimension change non-linearly as a function of a pressure applied to the contact lens.

Abstract: Provided herein are pharmaceutical compositions and methods treating Demodex or a disorder thereof around the eye by application of a metered dose of a semi-solid product from a product tube.

Abstract: Retinal imaging systems and related methods employ a user specific approach for controlling the reference arm length in an optical coherence tomography (OCT) imaging device. A method includes restraining a user's head relative to an OCT imaging device. A reference arm length adjustment module is controlled to vary a reference arm length to search a user specific range of reference arm lengths to identify a reference arm length for which the OCT image detector produces an OCT signal corresponding to the retina of the user. The user specific range of reference arm lengths covers a smaller range of reference arm lengths than a reference arm length adjustment range of the reference arm length adjustment module.

Abstract: Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

Abstract: Dynamic contact lenses fabricated with a dynamic portion that extends outward from the peripheral portion are disclosed. When worn on an eye the dynamic portion forms a tear lens for correcting vision. The dynamic portion can also be configured to provide a dynamic tear lens that changes optical power with forces applied by eyelids. The dynamic portion can be configured to assume a conforming configuration and at least one non-conforming configuration, or can be configured to assume at least two non-conforming configurations. The dynamic contact lenses can be used for correcting vision such as correcting presbyopia.

Abstract: Provided herein are pharmaceutical compositions and methods treating a disorder or disease around the eye by application of a low-volume, metered dose of a semi-solid selenium disulfide product.

Abstract: Described herein are compositions and methods for the treatment of contact lens discomfort (CLD) and/or lid wiper epitheliopathy (LWE). Such compositions comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of such compositions to the inner surface of the eyelid provides therapeutic benefit to patients suffering from contact lens discomfort (CLD) and/or lid wiper epitheliopathy (LWE).

Abstract: Described herein are compositions and methods for the increasing the quantity of lipids secreted from meibomian glands. Such compositions and methods are useful for the treatment of meibomian gland dysfunction and disorders resulting therefrom.

Abstract: Ophthalmic imaging systems and related methods provide pseudo feedback to aid a user in aligning the user's eye with an optical axis of the imaging system. An ophthalmic imaging system includes an ophthalmic imaging device having an optical axis, a display device, an eye camera, and a control unit. The display device displays a fixation target viewable by the user. The eye camera images the eye to generate eye image data. The control unit processes the eye image data to determine a position of the eye relative to the optical axis, processes the position of the eye relative to the optical axis to generate a pseudo position of the eye relative to the optical axis, and causes the display device to display an indication that provides feedback to the user that the eye is located at the pseudo position of the eye relative to the optical axis.

Abstract: Described herein are compositions and methods for the treatment of contact lens discomfort (CLD) and/or lid wiper epitheliopathy (LWE). Such compositions comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of such compositions to the inner surface of the eyelid provides therapeutic benefit to patients suffering from contact lens discomfort (CLD) and/or lid wiper epitheliopathy (LWE).

Abstract: Provided herein are methods treating a disease or disorder in or around the eye with a pharmaceutical composition comprising selenium disulfide (SeS2) and instructing the treated individual to limit or avoid exposure to light following administration in order to reduce the adverse effect of the composition.

Abstract: Ophthalmic imaging devices and related methods employ self-alignment of a user with an optical axis of the imaging device. An ophthalmic imaging device includes a retinal imaging assembly, a housing assembly, and a viewer assembly. The retinal imaging assembly has an optical axis. The retinal imaging assembly is attached to the housing. The housing assembly is configured to rest on a horizontal surface during operation of the retinal imaging assembly. The optical axis is oriented at an angle from the horizontal surface when the housing assembly rests on the horizontal surface. The viewer assembly is coupled with the housing assembly. The viewer assembly includes an interface surface shaped for engagement with each head of a plurality of different user's and to accommodate repositioning of the head to align a pupil of the user with the optical axis.

Abstract: Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said methods are performed by administering said composition comprising a selenium disulfide and an anhydrous semi-solid base. The stable anhydrous composition are substantially free of selenium disulfide agglomerates.

Abstract: Described herein are compositions and methods for the treatment of contact lens discomfort (CLD) and/or lid wiper epitheliopathy (LWE). Such compositions comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of such compositions to the inner surface of the eyelid provides therapeutic benefit to patients suffering from contact lens discomfort (CLD) and/or lid wiper epitheliopathy (LWE).

Abstract: Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said compositions and methods comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from meibomian gland dysfunction.

Abstract: Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory/infections disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugate which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eye, ocular surface or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

Abstract: Ophthalmic imaging devices and related methods employ self-alignment of a user with an optical axis of the imaging device. An ophthalmic imaging device includes an imaging assembly having an optical axis, a housing assembly, and a viewer assembly. The housing assembly is configured to rest on a horizontal surface during operation of the imaging assembly. The optical axis is oriented at an angle from 45 degrees to 85 degrees from the horizontal surface. The viewer assembly includes an interface surface shaped to engage a user's head to stabilize a position and an orientation of the user's head relative to the optical axis. The viewer assembly accommodates different positions and/or orientations of the user's head relative to the optical axis so as to enable alignment, by the user, of one of the user's eyes with the optical axis.

Abstract: Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said methods are performed by administering said composition comprising a selenium disulfide and an anhydrous semi-solid base. The stable anhydrous composition are substantially free of selenium disulfide agglomerates.